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Aim: To evaluate the safety and efﬁcacy of biphasic insulin aspart 30 (BIAsp 30) in patients with type 2
diabetes under routine clinical practice.
Study design: There were no prescribed procedures for this study except for the collection of data.
Result: Data obtained at baseline and Week 26 in patients from the Gulf region is presented. From the
Gulf region, 1613 patients (61% males) were enrolled with a mean age of 50.5 years and a mean BMI
of 30.4 kg/m2. The majority of the patients (57.0%) were treated with OAD only, while 34.3% patients
were previously treated with insulin ±OAD and 8.7% were treatment naive. After 26 weeks of treatment,
the mean HbA1c was reduced by 1.4% from 9.3% at baseline to 7.9% at Week 26. The mean FBG was
reduced by 66.6 mg/dL from 212.4 mg/dL at baseline to 145.8 mg/dL at Week 26. No major hypoglycae-
mic episodes were reported as SADRs during the study. The rate of major hypoglycaemic episodes was
reduced from 0.13 episodes/patient year at baseline to 0.05 episodes/patient year at Week 26. A lower
risk of minor hypoglycaemia was also observed. Body weight was reduced by 0.6 kg from 85.4 kg at base-
line to 84.7 kg at Week 26.
Conclusion: BIAsp 30 improved glycaemic control without increasing the risk of hypoglycaemic episodes
and weight gain after 26 weeks’ treatment in patients with type 2 diabetes from the Gulf region.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Type 2 diabetes is characterised by chronic hyperglycaemia
caused by the combination of insulin resistance and a progressive
decline in insulin secretion [1]. However, both fasting and post-
prandial blood glucose (PPBG) levels contribute to the HbA1c level
which reﬂects the mean glucose control for the preceding
3 months [2]. It is anticipated that postprandial hyperglycaemia
is more closely associated with an increased risk of macro-vascular
disease [3]. The Diabetes Epidemiology: Collaborative Analysis of
Diagnostic Criteria in Europe (DECODE) indicates that macro-vas-
cular disease has a stronger association with postprandial hyper-
glycaemia than with fasting hyperglycaemia [4]. Therefore, it
seems reasonable to target postprandial hyperglycaemia, in addi-
tion to fasting blood glucose (FBG) levels, to achieve maximumellitus. Published by Elsevier Ltd.
r).
Obeneﬁts. In this sense, the basal only therapy may be inadequate
in glycaemic control (especially controlling post prandial hyper-
glycaemia) in some patients. Either a basal-bolus or a premixed
insulin regimen is suggested at this point [5].
Biphasic insulin aspart 30/70 (BIAsp 30) (NovoMix30) is an
insulin analogue mixture which contains 30% unbound rapid-act-
ing insulin aspart and 70% intermediate-acting protaminated insu-
lin aspart. This premix formulation aims at targeting postprandial
hyperglycaemia as well as providing a basal insulin supplementa-
tion [6]. The 1-2-3 study has demonstrated that initiation of once-
daily BIAsp 30 in poorly controlled type 2 diabetes patients was
effective in achieving glycaemic goals. With the increase of daily
injections from one to two, and from two to three, more patients
could safely achieve glycaemic goals [7]. The INITIATE™ study indi-
cated that BIAsp 30 was more effective than insulin glargine in
achieving targeted HbA1c levels in insulin-naive patients who had
poorly controlled blood glucose levels in concomitant treatment
with OADs. In this study, the HbA1c was reduced by 2.9% andpen access under CC BY-NC-ND license.
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another treat-to-target study in insulin-naïve patients with type 2
diabetes poorly controlled with OADs (sulphonylureas with or
without metformin, or metformin mono-therapy), starting with
twice daily BIAsp 30 in combination with metformin reduced
HbA1c to a greater extent than once daily insulin glargine and glim-
epiride. The treatment difference was 0.5% (95% CI: 0.8; 0.2)
[9,10]. The safety and efﬁcacy were also conﬁrmed by an earlier re-
port on eight countries participating in the IMPROVE™ study and
by the OnceMix study with once-daily BIAsp 30 treatment [11,12].
Observational studies are considered to be a valuable supple-
ment for randomized clinical trials (RCTs) as a tool to evaluate
the safety and efﬁcacy of drugs in a heterogeneous population un-
der routine clinical practice [13,14]. Therefore, IMPROVE™, a large,
multi-national, observational study has been carried out to inves-
tigate the safety and effectiveness of BIAsp 30 in the treatment of
type 2 diabetes under the routine clinical practice. The results from
the Gulf region are reported in this paper.Table 1
Analysis sets.
Number of patients N
(%)
Number of patients in FAS 1613
Number of patients in EAS 1136 (70.4)
Number of patients in FAS excluded from EAS 477 (29.6)
By reason of exclusion
No ﬁnal visit 224 (13.9)
No measurement at baseline and Week 26a 47 (2.9)
Final visit outside range 18–34 weeks from
baseline
195 (12.1)
Baseline or ﬁnal visit dates are missing 11 (0.7)
Number of patients
Who completed the study 1456 (90.3)
Who discontinued the study 157 (9.7)
By reason of discontinuation
Lost contact 128 (7.9)
Adverse drug reaction 9 (0.6)
Other reasons 27 (1.7)
FAS, full analysis set; EAS, efﬁcacy analysis set.
a Not having at least one measurement concerning blood glucose, HbA1c, weight
or hypoglycaemic episodes at baseline and ﬁnal visit.2. Methods
IMPROVE™was a 26-week, open-label, non-randomized, multi-
centre observational study of patients with type 2 diabetes carried
out in 11 countries (Canada, China, Greece, Gulf region, India, Iran,
Italy, Japan, Poland, Russia and South Korea) [15,16]. The results in
patients with type 2 diabetes from the Gulf region, including Saudi
Arabia, United Arab Emirates, Kuwait, Qatar and Oman are pre-
sented in this paper. Patients who initiated insulin therapy with,
or switched existing insulin therapy to BIAsp 30 in routine care
were eligible. There were no study-prescribed procedures for this
study.
The study was conducted in accordance with the Declaration of
Helsinki, and complied with local regulations governing observa-
tional studies with regards to health authority and ethics commit-
tee approval, as well as patient informed consent.
The primary endpoint was the incidence of major hypoglycae-
mic events reported as serious adverse drug reactions (SADRs). A
major hypoglycaemic episode was deﬁned as an episode with se-
vere central nervous system symptoms consistent with hypogly-
caemia, in which the patient was unable to treat himself/herself
with/without measurement of blood glucose < 50 mg/dL
(2.8 mmol/L) or reversal of symptoms after either food intake or
glucagon or intravenous glucose administration. A minor hypogly-
caemic episode was deﬁned as an episode with symptoms of hypo-
glycaemia with the conﬁrmation of blood glucose
measurement < 56 mg/dL (3.1 mmol/L) and which was handled
by the patient or any asymptomatic blood glucose measure-
ment < 56 mg/dL (3.1 mmol/L).
Data were collected at baseline (Visit 1), at the follow-up visit
(Visit 2) at approximately 13 weeks, and at the ﬁnal visit (Visit 3)
at approximately 26 weeks. Results from baseline and Week 26
are presented in this report.
The summary of the baseline characteristics and safety data
were based on Full Analysis Set (FAS), which consisted of all pa-
tients with a baseline visit, which had been prescribed BIAsp 30
at least once and did not use BIAsp 30 before the start of the study.
The analysis of the efﬁcacy outcome variables were based on Efﬁ-
cacy Analysis Set (EAS), which was deﬁned as all patients from FAS
who had the Week 26 visit, at least one measurement concerning
FBG, PPG, most recent HbA1c, weight or hypoglycaemic episodes
at baseline and Week 26, with the ﬁnal visit within 18 to 34 weeks
from baseline.
Descriptive statistics were used to summarize HbA1c, body
weight and the daily dose of BIAsp 30 at baseline and Week 26
and the absolute changes from baseline. Paired t-test was used tocompare HbA1c, body weight and the daily dose of BIAsp 30 at
baseline and Week 26. The test was performed only if values at
both visits were present. The occurrence of hypoglycaemic epi-
sodes was evaluated as episodes per patient year. All testing used
two-sided tests with the signiﬁcant level set at a = 0.05. All analy-
sis was performed using SAS, Version 9.1 (SAS Institute, Cary, NC).3. Results
3.1. Baseline demographics
An overview of patient disposition from the Gulf region is
shown in Table 1. The FAS included 1613 patients, while there
were 1136 (70.4%) patients in the EAS. A total of 477 patients
(29.6%) in the FAS were excluded from the EAS, in which 224
(13.9%) had no ﬁnal visits, 195 (12.1%) had the ﬁnal visit outside
the range of 18–34 weeks from baseline, 47 (2.9%) had no mea-
surement at baseline and Week 26 and 11 (0.7%) had missing base-
line or ﬁnal visit date. A total of 157 (9.7%) patients discontinued
from the study due to ‘‘lost contact” (128 patients, 7.9%), ‘‘ADR”
(nine patients, 0.6%) or ‘‘other reasons” (27 patients, 1.7%).
The complete demographic characteristics of all patients from
the Gulf region and the reasons for initiating a new therapy are
summarised in Table 2. The patients had a mean age of
50.5 ± 10.4 years, with a higher proportion of males (male: fe-
male = 60.8/39.2). The mean BMI was 30.4 ± 5.3 kg/m2 and the
mean diabetes duration was 10.1 ± 5.8 years. They were treat-
ment-naïve (8.7%) or previously treated with OADs only (57.0%)
and/or insulin (34.3%). The most cited reason for starting a new
therapy was to improve glycaemic control (to improve HbA1c:
83.6%, to improve FBG: 81.8%, to improve PPBG: 74.3%) (Table 2).
3.2. Safety
The primary endpoint was the incidence of major hypoglycae-
mic events reported as serious adverse drug reactions, during
26 weeks of BIAsp 30 therapy. No major hypoglycaemic episodes
were reported as SADRs during the study. In total, 1 SADR was
reported in this study and it was moderate. The patient fully
recovered from the SADR.
The rates ofmajor andminor hypoglycaemic episodes are shown
as episodes/patient year in Fig 1. The rate of major hypoglycaemic
Table 2
Demography and reasons for initiating new therapy.
FAS
Age, years
N 1121
Mean (SD) 50.5 (10.4)
Gender, N (%)
Female 628 (39.2)
Male 972 (60.8)
BMI, kg/m2
N 1495
Mean (SD) 30.4 (5.3)
Duration of diabetes, years
N 1554
Mean (SD) 10.1 (5.8)
Reason(s) for starting a new therapy, %
Easy start of insulin therapy 46.2
Easy intensiﬁcation of insulin therapy 38.0
Improve HbA1c 83.6
Improve FBG 81.8
Improve PPBG 74.3
Reduce risk of hypoglycaemia 25.1
Patient dissatisfaction with previous therapy 35.0
Side effects from previous therapy 17.1
Change due to insulin pen 28.6
Allow for mealtime administration 22.9
Missing 0.4
N reads the number of subjects in FAS with non-missing value, country speciﬁc.
Percentages are based on the total number of subjects in FAS, country speciﬁc.
A subject may have ﬁndings in more than one category.
Table 3
Efﬁcacy parameters.
Parameter (SD) Baseline Week 26 Absolute change
Mean HbA1c, %Hb 9.3 (2.8) 7.9 (1.7) 1.4 (2.3)*
Mean FBG, mmol/L 212.4 (64.8) 145.8 (41.4) 66.6 (55.8)*
Mean PPG, mmol/L
At breakfast 291.6 (81.0) 158.4 (41.4) 135.0 (82.8)*
At lunch 280.8 (77.4) 165.6 (34.2) 115.2 (79.2)*
At dinner 279.0 (86.4) 163.8 (37.8) 115.2 (91.8)*
Body weight, kg 85.4 (16.6) 84.7 (15.3) 0.6 (4.1)*
BMI, kg/m2 30.5 (5.5) 30.3 (5.2) 0.2 (.1.5)*
FBG, fasting blood glucose; PPG, post prandial glucose; NS, not signiﬁcant.
* p < 0.001.
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to 0.05 episodes/patient year at Week 26. The similar pattern
was also observed for both diurnal (from 0.08 episodes/patient
year at baseline to 0.04 episodes/patient year) and nocturnal
hypoglycaemic episodes (from 0.05 episodes/patient year at
baseline to 0.02 episodes/patient year). The rate of minor hypogly-
caemic episodes decreased from 6.08 episodes/patient year at
baseline to 3.83 episodes/patient year. Similarly, diurnal and
nocturnal minor episodes also decreased from 4.43 episodes/pa-
tient year at baseline to 2.94 episodes/patient year (diurnal) and
from 1.66 episodes/patient year at baseline to 0.89 episodes/patient
year (nocturnal).
3.3. Efﬁcacy
After 26 week’s treatment with BIAsp 30, HbA1c was reduced by
1.4 ± 2.3% from 9.3 ± 2.8% at baseline to 7.9 ± 1.7% at the end of the
study (Table 3). The proportion of patients who achieved the target
of HbA1c 6 6.5% was slightly reduced from 7.6% at baseline to 5.4%
at Week 26, while the proportion of patients who achieved theFig. 1. Number of hypoglycaemic eptarget of HbA1c < 7.0% was increased from 8.8% at baseline to
15.0% at Week 26. The mean FBG was reduced by 66.6 ± 55.8 mg/
dL from 212.4 ± 64.8 mg/dL at baseline to 145.8 ± 41.4 mg/dL at
Week 26. Decrease in PPBG at breakfast, lunch and dinner were
also observed (Table 3).3.4. Body weight and insulin dose
The mean daily dose of BIAsp 30 increased by 12.2 U (0.15 U/kg)
from 46.8 U (0.56 U/kg) at baseline to 59.0 U (0.71 U/kg) at Week
26. Body weight was reduced by 0.6 ± 4.1 kg from 85.4 ± 16.6 kg at
baseline to 84.7 ± 15.3 kg at Week 26. Accordingly, BMI was re-
duced by 0.22 ± 1.46 kg/m2 from 30.49 ± 5.51 kg/m2 at baseline
to 30.28 ± 5.17 kg/m2 at Week 26.4. Discussion
Although there is no published data on the prevalence of type 2
diabetes in the Gulf region, it seems that the population has the
highest rate in the world, which is reaching 35% in some areas
[17]. It is believed that the increases in obesity and metabolic syn-
drome, induced by oil wealth and the subsequent alteration of life-
style, lead to a type 2 diabetes pandemic of as high as 1 in 2 people
in Gulf, which has a serious impact on general health and absolute
life expectancy [18]. The grim situation, as also demonstrated by
the baseline data from the IMPROVE study [15], warrants extensive
studies on the current status and treatments of type 2 diabetes
from the Gulf region, which are crucial to the overall management
strategy.
The IMPROVE™ study was a 26-week, large, multi-centre obser-
vational study conducted in 11 countries in patients with type 2
diabetes. The aim of this study was to investigate the clinicalisodes (episodes/patient years).
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countries. Safety and efﬁcacy assessments were performed at base-
line, at Week 13 and at Week 26. The results from the Gulf region
of the IMPROVE study are presented in this paper. The present pa-
per demonstrates that treatment with BIAsp 30 was a safe (with a
low risk of hypoglycaemic episodes) and effective therapy (with an
improvement in glycaemic control) in patients with type 2 diabe-
tes from the Gulf countries.
The incidence of major hypoglycaemic episodes assessed as
SADRs was the primary endpoint. No major hypoglycaemic episode
was reported as SADRs during the study. In Gulf countries, the
rates of both major and minor hypoglycaemic episodes as epi-
sodes/patient year were reduced from baseline to the ﬁnal visit
at Week 26 (62% and 37%, respectively), while a lower risk of
major episodes and no difference in minor episodes were observed
in the global IMPROVE™ study [11].
After 26 weeks of treatment with BIAsp 30, an improvement in
glycaemic control was shown. The HbA1c in patients from the Gulf
region was reduced from 9.3% at baseline to 7.9% at Week 26,
which was slightly less compared to the decrease in the global IM-
PROVE™ study (9.3% at baseline to 7.1% at Week 26). The differ-
ence might be due to the higher percentage of patients with no
or OAD-only pre-treatment in the global cohort (81.6% in the global
cohort versus 65.7% in patients from the Gulf region). At baseline, a
poor glycaemic control (HbA1c: 9.3%) and high rates of microvascu-
lar complications (63.8%) and macro-vascular complications
(43.4%) were observed, which warranted the need of an earlier ini-
tiation of insulin therapy. Although the HbA1c level has been re-
duced by 1.4% from the baseline after 26 weeks of treatment
with BIAsp 30, the proportion of patients who achieved the target
of HbA1c < 7.0% or 66.5% was low. The 1–2–3 study demonstrated
that the initiation of once daily treatment with BIAsp 30, using an
intense titration schedule enabled 21% patients to achieve
HbA1c 6 6.5% (41% achieved HbA1c < 7.0%). Additional patients
safely achieved these goals when the number of daily injections
was increased from one to two, and then if not meeting those
HbA1c targets, from two to three daily injections. With three daily
injections of BIAsp 30, these glycaemic goals were achieved in 60%
and 77% patients respectively [7]. In contrast, our study was an
observational study without set titration schedule. With physi-
cians focusing more on dose optimisation and titration the HbA1c
level at Week 26 (7.9%) could be further reduced, and more
patients could achieve the targets of glycaemic control with
intensiﬁed titrations as also conﬁrmed in other randomized clinical
trials[8–10]. The proportion of patients who achieved the target of
HbA1c 6 6.5% was slightly reduced from 7.6% at baseline to 5.4% at
Week 26, which could be explained by the random errors and
ﬂuctuations that might occur, given the small number of patients
involved. Furthermore, the decrease in both FBG and PPG indicated
that BIAsp 30 provides basal insulin coverage as well as postpran-
dial coverage. This was consistent with the ﬁnding in clinical trials
and the global IMPROVE™ study [6,11,15]. No clinical relevant
change in body weight was found after 26 weeks of treatment with
BIAsp 30.
Overall, the ﬁndings from the Gulf region were comparable to
those from the IMPROVE™ global study. The study was limited
by the potential patient recall bias.
In conclusion, the treatment with BIAsp 30 improved glycaemic
control measured as mean HbA1c without increasing the risk of
hypoglycaemic episodes and weight gain in poorly controlled pa-
tients with type 2 diabetes in various pre-study treatments, in
the Gulf countries. Our study provided valuable information of
the treatment of type 2 diabetes under ‘real-life’ clinical practice
as complementary data for RCTs. The low proportion of patientsachieving glycaemic control targets observed in this study rein-
forces the importance of reminding physicians of dose optimisa-
tion/titration and intensiﬁcation. It is helpful for the better
understanding and management of the disease in the Gulf region,
which has far-reaching beneﬁts across all socioeconomic classes,
given the rapid increase of the prevalence of type 2 diabetes in
these countries.
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